Access to the latest research — for scientists and people living with PD alike — in PDF's new scientific journal.
Teva Hails Milder Restrictions on Parkinson's Drug
- Dec 15 2009
Note from PDF: The article below details a labeling change for the Parkinson's medication rasagiline (Azilect (R)).Christopher Goetz, M.D., Chair of PDF's Medical Policy Committee and Director of the PDF Parkinson's Disease Research Center at Rush University Medical Center in Chicago, notes the following about this label change,
"This change in labeling simply means that a person with Parkinson's who is taking the medication, rasagiline, need not worry about moderate intake of tyramine-rich foods (i.e., salami, cheese and other foods). However, in advising my own patients, I will still suggest that they avoid very high tyramine-enriched diets or eating large amounts of tyramine-rich foods at one sitting." For more information, please view PDF's medication chart.
NEW YORK — Teva Pharmaceutical Industries Ltd. said Monday U.S. health regulators scaled back dietary and health restrictions on its Parkinson's Disease drug Azilect.
Teva said the new labeling eases concerns about drug interactions with other medications, including over-the-counter cold medicines.
The new labeling also states that patients no longer have to follow general dietary restrictions on levels of tyramine, an amino acid found in certain foods, including air-dried and fermented meats. Because of increased sensitivity in some patients, however, the new labeling recommends against high levels of the acid.
The Food and Drug Administration approved Azilect in 2006 as a daily treatment for Parkinson's Disease.
Shares of Teva Pharmaceutical Industries Inc. fell 9 cents to $53.40 in after-hours trading.
Copyright © 2009 The Associated Press. All rights reserved.
Source Date: Dec 14 2009
Source Publication: Associated Press
View source URL